Position in ABSI
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$9,059,810
+$7,469,420 QoQ
Shares Held
781,692
+47.5% QoQ
Ownership
0.455%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#34
of 195 holders
Holding Since
Mar 2025
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ABSI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026LAZARD ASSET MANAGEMENT LLC holds $400,660,289 across 59 Biotechnology names. ABSI ranks #12 (2.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ARGX |
Argenx SE
|
131,996 | $122,461,928 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
93,287 | $46,338,451 | |
| 3 | ONC |
BeOne Medicines Ltd.
|
90,348 | $25,746,469 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
36,910 | $23,014,861 | |
| 5 | BMRN |
Biomarin Pharmaceutical Inc
|
350,397 | $20,049,716 | |
| 6 | EXEL |
Exelixis, Inc.
|
343,029 | $18,664,207 | |
| 7 | JAZZ |
Jazz Pharmaceuticals plc
|
69,588 | $16,768,620 | |
| 8 | INCY |
Incyte Corp
|
136,684 | $15,494,498 |
All Filings in ABSI
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $9,059,810 | 781,692 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $1,590,390 | 530,130 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $1,938,202 | 555,359 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $1,968,506 | 647,535 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $942,948 | 366,906 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $753,878 | 300,350 | Shares | Sole | 2025-05-15 | |
| No filing history on record for this holder in this stock. | ||||||